WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2023 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 11, 2023, at 9:20 a.m. ET.

To access the live event, please click here to register for the webcast. The archived webcast will also be available on the Company’s website under the “Events & Presentations” page in the “Investors” section for approximately 90 days following the presentation.

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also developing a novel small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Megan McGrath
MacDougall Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.